Research Paper Volume 12, Issue 14 pp 14897—14917

Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson’s disease models through activating the MEF2-PGC1α and BDNF/CREB pathways

Figure 1. T-006 improves motor behavior, protects nigrostriatal neurons, and suppresses disease progression in mice subjected to MPTP. (A) Schedule for T-006 treatment of a chronic MPTP mice PD model. (B) The changes of body weight in different groups (n=14-16 per group). (C) Time spent on pole. (D) Time taken for the left forelimb to grip wire. (E) Distance between hind paws’ markings on white absorbing paper. (F) Distance travelled (cm) in open field. (G) Immunohistochemistry for TH in the substantia nigra (SN; upper panel) and striatum (ST; lower panel) of MPTP mice. (H) Stereological counting of TH-positive DA neurons from SN. (I) Relative density of TH-positive neuronal fibers in ST. (J) Representative Western blots illustrating the expression of TH in SN and ST. (K) Densitometric analysis of TH/β-actin of treatment with T-006 at the indicated concentrations in SN and ST. The results are shown as the mean±SEM (n=6-8 per group). (L) Striatal dopamine and its metabolites DOPAC and HVA were analyzed by electrochemical HPLC with 6 to 8 mice per group. Data are expressed as mean±SEM. #P<0.05, ##P<0.01, ###P<0.001 vs. sham group, and *P<0.05, **P<0.01 and ***P<0.001vs. MPTP group.